Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

Bastide, Matthieu F ; Meissner, Wassilios G ; Picconi, Barbara ; Fasano, Stefania ; Fernagut, Pierre-Olivier ; Feyder, Michael ; Francardo, Veronica LU ; Alcacer, Cristina LU ; Ding, Yunmin and Brambilla, Riccardo , et al. (2015) In Progress in Neurobiology 132(Jul 21). p.96-168
Abstract
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system... (More)
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiological framework was timely and necessary. An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary. This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Progress in Neurobiology
volume
132
issue
Jul 21
pages
96 - 168
publisher
Elsevier
external identifiers
  • pmid:26209473
  • wos:000361404000005
  • scopus:84940452532
  • pmid:26209473
ISSN
1873-5118
DOI
10.1016/j.pneurobio.2015.07.002
language
English
LU publication?
yes
id
e5a6246e-f465-487d-972f-5547a1a3d1a7 (old id 7720896)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26209473?dopt=Abstract
date added to LUP
2016-04-01 11:12:16
date last changed
2022-05-13 23:36:48
@article{e5a6246e-f465-487d-972f-5547a1a3d1a7,
  abstract     = {{Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiological framework was timely and necessary. An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary. This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.}},
  author       = {{Bastide, Matthieu F and Meissner, Wassilios G and Picconi, Barbara and Fasano, Stefania and Fernagut, Pierre-Olivier and Feyder, Michael and Francardo, Veronica and Alcacer, Cristina and Ding, Yunmin and Brambilla, Riccardo and Fisone, Gilberto and Jon Stoessl, A and Bourdenx, Mathieu and Engeln, Michel and Navailles, Sylvia and De Deurwaerdère, Philippe and Ko, Wai Kin D and Simola, Nicola and Morelli, Micaela and Groc, Laurent and Rodriguez, Maria-Cruz and Gurevich, Eugenia V and Quik, Maryka and Morari, Michele and Mellone, Manuela and Gardoni, Fabrizio and Tronci, Elisabetta and Guehl, Dominique and Tison, François and Crossman, Alan R and Kang, Un Jung and Steece-Collier, Kathy and Fox, Susan and Carta, Manolo and Cenci Nilsson, Angela and Bézard, Erwan}},
  issn         = {{1873-5118}},
  language     = {{eng}},
  number       = {{Jul 21}},
  pages        = {{96--168}},
  publisher    = {{Elsevier}},
  series       = {{Progress in Neurobiology}},
  title        = {{Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.}},
  url          = {{http://dx.doi.org/10.1016/j.pneurobio.2015.07.002}},
  doi          = {{10.1016/j.pneurobio.2015.07.002}},
  volume       = {{132}},
  year         = {{2015}},
}